Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms and Coronary Heart Disease
Single nucleotide polymorphisms (SNPs) in the peroxisome proliferator-activated receptor γ (PPARG) gene have been associated with cardiovascular risk factors, particularly obesity and diabetes. We assessed the relationship between 4 PPARG SNPs (C-681G, C-689T, Pro12Ala, and C1431T) and coronary hear...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2009-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2009/543746 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567982205698048 |
|---|---|
| author | Jean Dallongeville Carlos Iribarren Jean Ferrières Liisa Lyon Alun Evans Alan S. Go Dominique Arveiler Stephen P. Fortmann Pierre Ducimetière Mark A. Hlatky Philippe Amouyel Audrey Southwick Thomas Quertermous Aline Meirhaeghe |
| author_facet | Jean Dallongeville Carlos Iribarren Jean Ferrières Liisa Lyon Alun Evans Alan S. Go Dominique Arveiler Stephen P. Fortmann Pierre Ducimetière Mark A. Hlatky Philippe Amouyel Audrey Southwick Thomas Quertermous Aline Meirhaeghe |
| author_sort | Jean Dallongeville |
| collection | DOAJ |
| description | Single nucleotide polymorphisms (SNPs) in the peroxisome proliferator-activated receptor γ (PPARG) gene have been associated with cardiovascular risk factors, particularly obesity and diabetes. We assessed the relationship between 4 PPARG SNPs (C-681G, C-689T, Pro12Ala, and C1431T) and coronary heart disease (CHD) in the PRIME (249 cases/494 controls, only men) and ADVANCE (1,076 cases/805 controls, men or women) studies. In PRIME, homozygote individuals for the minor allele of the PPARG C-689T, Pro12Ala, and C1431T SNPs tended to have a higher risk of CHD than homozygote individuals for the frequent allele (adjusted OR [95% CI] = 3.43 [0.96–12.27], P=.058, 3.41 [0.95–12.22], P=.060 and 5.10 [0.99–26.37], P=.050, resp.). No such association could be detected in ADVANCE. Haplotype distributions were similar in cases and control in both studies. A meta-analysis on the Pro12Ala SNP, based on our data and 11 other published association studies (6,898 CHD cases/11,287 controls), revealed that there was no evidence for a significant association under the dominant model (OR=0.99
[0.92–1.07], P=.82). However, there was a borderline association under the recessive model (OR=1.29 [0.99–1.67], P=.06) that became significant when considering men only (OR=1.73 [1.20–2.48], P=.003). In conclusion, the PPARG Ala12Ala genotype might be associated with a higher CHD risk in men but further confirmation studies are needed. |
| format | Article |
| id | doaj-art-0810e8153aa04b1a8c0f8528843e6147 |
| institution | Kabale University |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2009-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-0810e8153aa04b1a8c0f8528843e61472025-02-03T00:59:57ZengWileyPPAR Research1687-47571687-47652009-01-01200910.1155/2009/543746543746Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms and Coronary Heart DiseaseJean Dallongeville0Carlos Iribarren1Jean Ferrières2Liisa Lyon3Alun Evans4Alan S. Go5Dominique Arveiler6Stephen P. Fortmann7Pierre Ducimetière8Mark A. Hlatky9Philippe Amouyel10Audrey Southwick11Thomas Quertermous12Aline Meirhaeghe13Service d'Epidémiologie et de Santé Publique, Institut Pasteur de Lille, Lille; INSERM, U744, Lille; Université Nord de France, Lille; UDSL, 59019 Lille, FranceKaiser Permanente Division of Research, Oakland, CA 94612, USAINSERM, U558, Toulouse, Department of Epidemiology, Paul Sabatier-Toulouse Purpan University, 31073 Toulouse, FranceKaiser Permanente Division of Research, Oakland, CA 94612, USAThe Department of Epidemiology and Public Health, Queen’s University Belfast, Belfast BT71NN, Northern Ireland, UKKaiser Permanente Division of Research, Oakland, CA 94612, USADepartment of Epidemiology and Public Health, EA 3430, University of Strasbourg, Faculty of Medicine, 67085 Strasbourg, FranceStanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA 94305-5705, USAINSERM, U780, 94807 Villejuif, Hôpital Kremlin-Bicêtre, FranceDepartment of Health Research and Policy, Stanford University School of Medicine, Stanford, CA 94305, USAService d'Epidémiologie et de Santé Publique, Institut Pasteur de Lille, Lille; INSERM, U744, Lille; Université Nord de France, Lille; UDSL, 59019 Lille, FranceStanford Human Genome Center, Stanford, CA 94304, USAFalk Cardiovascular Research Center, Stanford Falk Cardiovascular Research Building, Stanford, CA 94305-5406, USAService d'Epidémiologie et de Santé Publique, Institut Pasteur de Lille, Lille; INSERM, U744, Lille; Université Nord de France, Lille; UDSL, 59019 Lille, FranceSingle nucleotide polymorphisms (SNPs) in the peroxisome proliferator-activated receptor γ (PPARG) gene have been associated with cardiovascular risk factors, particularly obesity and diabetes. We assessed the relationship between 4 PPARG SNPs (C-681G, C-689T, Pro12Ala, and C1431T) and coronary heart disease (CHD) in the PRIME (249 cases/494 controls, only men) and ADVANCE (1,076 cases/805 controls, men or women) studies. In PRIME, homozygote individuals for the minor allele of the PPARG C-689T, Pro12Ala, and C1431T SNPs tended to have a higher risk of CHD than homozygote individuals for the frequent allele (adjusted OR [95% CI] = 3.43 [0.96–12.27], P=.058, 3.41 [0.95–12.22], P=.060 and 5.10 [0.99–26.37], P=.050, resp.). No such association could be detected in ADVANCE. Haplotype distributions were similar in cases and control in both studies. A meta-analysis on the Pro12Ala SNP, based on our data and 11 other published association studies (6,898 CHD cases/11,287 controls), revealed that there was no evidence for a significant association under the dominant model (OR=0.99 [0.92–1.07], P=.82). However, there was a borderline association under the recessive model (OR=1.29 [0.99–1.67], P=.06) that became significant when considering men only (OR=1.73 [1.20–2.48], P=.003). In conclusion, the PPARG Ala12Ala genotype might be associated with a higher CHD risk in men but further confirmation studies are needed.http://dx.doi.org/10.1155/2009/543746 |
| spellingShingle | Jean Dallongeville Carlos Iribarren Jean Ferrières Liisa Lyon Alun Evans Alan S. Go Dominique Arveiler Stephen P. Fortmann Pierre Ducimetière Mark A. Hlatky Philippe Amouyel Audrey Southwick Thomas Quertermous Aline Meirhaeghe Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms and Coronary Heart Disease PPAR Research |
| title | Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms and Coronary Heart Disease |
| title_full | Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms and Coronary Heart Disease |
| title_fullStr | Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms and Coronary Heart Disease |
| title_full_unstemmed | Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms and Coronary Heart Disease |
| title_short | Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms and Coronary Heart Disease |
| title_sort | peroxisome proliferator activated receptor gamma polymorphisms and coronary heart disease |
| url | http://dx.doi.org/10.1155/2009/543746 |
| work_keys_str_mv | AT jeandallongeville peroxisomeproliferatoractivatedreceptorgammapolymorphismsandcoronaryheartdisease AT carlosiribarren peroxisomeproliferatoractivatedreceptorgammapolymorphismsandcoronaryheartdisease AT jeanferrieres peroxisomeproliferatoractivatedreceptorgammapolymorphismsandcoronaryheartdisease AT liisalyon peroxisomeproliferatoractivatedreceptorgammapolymorphismsandcoronaryheartdisease AT alunevans peroxisomeproliferatoractivatedreceptorgammapolymorphismsandcoronaryheartdisease AT alansgo peroxisomeproliferatoractivatedreceptorgammapolymorphismsandcoronaryheartdisease AT dominiquearveiler peroxisomeproliferatoractivatedreceptorgammapolymorphismsandcoronaryheartdisease AT stephenpfortmann peroxisomeproliferatoractivatedreceptorgammapolymorphismsandcoronaryheartdisease AT pierreducimetiere peroxisomeproliferatoractivatedreceptorgammapolymorphismsandcoronaryheartdisease AT markahlatky peroxisomeproliferatoractivatedreceptorgammapolymorphismsandcoronaryheartdisease AT philippeamouyel peroxisomeproliferatoractivatedreceptorgammapolymorphismsandcoronaryheartdisease AT audreysouthwick peroxisomeproliferatoractivatedreceptorgammapolymorphismsandcoronaryheartdisease AT thomasquertermous peroxisomeproliferatoractivatedreceptorgammapolymorphismsandcoronaryheartdisease AT alinemeirhaeghe peroxisomeproliferatoractivatedreceptorgammapolymorphismsandcoronaryheartdisease |